Skip to main content
Premium Trial:

Request an Annual Quote

Peter Johnson, Mark Braughler, Todd Joron, Max Fedor, F. Mark Modzelewski, Andrew Mullen

Premium

Paradigm Genetics said it will acquire TissueInformatics, and said that the smaller company’s management team will join Paradigm’s payroll (see SNIPPETS, page 6). Specifically, Peter Johnson, chairman and CEO of TissueInformatics, will become executive vice president and chief medical officer at Paradigm; and Mark Braughler, senior vice president of business development at TissueInformatics, will become vice president of healthcare business development at Paradigm.

Also, Todd Joron, a senior vice president of TissueInformatics, will head the company’s software business, while Max Fedor, vice president of product development, will oversee product development of that business unit.


CombiMatrix has named Nanobusiness Alliance executive director F. Mark Modzelewski to its scientific advisory board.

A member of the Nanotechnology Technical Advisory Group to President George W. Bush’s Council of Advisors on Science and Technology, Modzelewski taught classes on the business of nanotechnology at Northwestern’s Kellogg School and New York University’s Stern School of Business.

Modzelewski is a graduate of the University of Denver College of Law and Boston University. CombiMatrix is a unit of Acacia Research.


PerkinElmer has appointed Biogen Idec CEO Andrew Mullen to its board of directors. Mullen, who was formerly chairman and CEO of Biogen, held various positions at SmithKline Beecham, now GlaxoSmithKline. He holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

 

Filed under

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.